Citigroup Inc Ac Immune Sa Transaction History

Citigroup Inc

$190 Billion
Q1 2025

A detailed history of Citigroup Inc transactions in Ac Immune Sa stock. As of the latest transaction made, Citigroup Inc holds 1,439 shares of ACIU stock, worth $2,949. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,439

Previous 2,727 47.23%

Holding current value

$2,949

Previous $7,000 71.43%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$1.87 - $2.98 $2,408 - $3,838	-1,288 Reduced 47.23%	1,439 $2,000
Q4 2024 Feb 12, 2025	BUY	$2.67 - $3.75 $2,592 - $3,641	971 Added 55.3%	2,727 $7,000
Q3 2024 Nov 12, 2024	SELL	$2.99 - $4.2 $1,016 - $1,428	-340 Reduced 16.22%	1,756 $6,000
Q2 2024 Aug 12, 2024	BUY	$2.29 - $4.87 $4,089 - $8,697	1,786 Added 576.13%	2,096 $8,000
Q1 2024 May 10, 2024	SELL	$2.66 - $4.87 $3,202 - $5,863	-1,204 Reduced 79.52%	310 $0
Q4 2023 Feb 09, 2024	BUY	$2.46 - $5.0 $3,724 - $7,570	1,514 New	1,514 $7,000
Q1 2023 May 11, 2023	BUY	$2.13 - $2.49 $1.85 Million - $2.17 Million	870,179 New	870,179 $2.04 Million
Q3 2022 Nov 10, 2022	SELL	$2.4 - $3.64 $684 - $1,037	-285 Reduced 23.69%	918 $3,000
Q2 2022 Aug 10, 2022	SELL	$2.35 - $4.47 $1,167 - $2,221	-497 Reduced 29.24%	1,203 $4,000
Q1 2022 May 12, 2022	SELL	$3.5 - $5.16 $2,474 - $3,648	-707 Reduced 29.37%	1,700 $7,000
Q4 2021 Feb 10, 2022	SELL	$4.83 - $7.56 $9,128 - $14,288	-1,890 Reduced 43.98%	2,407 $12,000
Q3 2021 Nov 10, 2021	BUY	$6.2 - $8.34 $26,641 - $35,836	4,297 New	4,297 $29,000

Others Institutions Holding ACIU

# of Institutions

Shares Held

27.4M

Call Options Held

4.8K

Put Options Held

22.2K

View Full List

About AC Immune SA

Ticker ACIU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,413,504
Market Cap $171M
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...

More about ACIU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account